Troriluzol Medicine 04 December 2025 Extended indication Troriluzole monotherapy for adjunctive treatment of obsessive-compulsive disorder in adults and elderly with an inadequate response to existing standard of care treatment. Therapeutic value No estimate possible yet Total cost Registration phase No registration expected Product Active substance Troriluzol Domain Neurological disorders Reason of inclusion New medicine (specialité) Main indication Other psychiatry Extended indication Troriluzole monotherapy for adjunctive treatment of obsessive-compulsive disorder in adults and elderly with an inadequate response to existing standard of care treatment. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Biohaven Portfolio holder Mechanism of action Other, see general comments Route of administration Oral Therapeutical formulation Capsule Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Glutamaatremmer Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date September 2025 Expected Registration Orphan drug Unknown Registration phase No registration expected Reimbursement Medicine sluice Additional remarks Klinische studie vroegtijdig gestopt. Therapeutic value Current treatment options SSRIs, clomipramine Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 2 times a day Dosage per administration 100 tot 140mg References NCT04641143 (BHV4157-302); NCT04693351 (BHV4157-303) Additional remarks Twee capsules van 100mg per dag gedurende de eerste twee weken en vervolgens twee capsules van 140mg per dag vanaf week twee tot en met week tien. Expected patient volume per year Patient volume < 50,000 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Radboudumc. Onderzoek naar behandeling voor therapieresistente dwangstoornis. 2021. Additional remarks In Nederland lijden minstens 100.000 mensen aan een obsessieve-compulsieve stoornis (OCS). Ongeveer de helft van mensen met OCS krijgt medicijnen of heeft deze geprobeerd als onderdeel van de behandeling. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks